Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day

[ad_1] Ad hoc announcement pursuant to Art. 53 LR  ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-term sales…

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

[ad_1] Ad hoc announcement pursuant to Art. 53 LR  Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz…